Patents by Inventor Sabine GEIGER-SCHREDELSEKER

Sabine GEIGER-SCHREDELSEKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT)
    Publication number: 20230226222
    Abstract: A method for treating a subject having a medical condition associated with inflammation and/or an unwanted immune response without an alpha1-antitrypsin (AAT) deficiency, wherein the method comprises administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells comprise an exogenous nucleic acid comprising (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 20, 2023
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT)
    Publication number: 20200282078
    Abstract: A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response, and said subject does not have an alpha1-antitrypsin (AAT) deficiency, wherein the method includes administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells include an exogenous nucleic acid including (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: February 25, 2020
    Publication date: September 10, 2020
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT)
    Publication number: 20180000969
    Abstract: Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • LENTIVIRAL VECTOR FOR STEM CELL GENE THERAPY OF SICKLE CELL DISEASE
    Publication number: 20170157270
    Abstract: In various embodiments a recombinant lentiviral vector is provided comprising an expression cassette comprising a nucleic acid construct comprising an anti-sickling human beta globin gene encoding an anti-sickling-beta globin polypeptide comprising the mutations Gly16Asp, Glu22Ala and Thr87Gln, where the lentiviral vector is a TAT-independent and self-inactivating (SIN). In certain embodiments the vector additionally contains one or more insulator elements. The vectors are useful in gene therapy for the treatment of sickle cell disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: June 8, 2017
    Inventors: Donald B. Kohn, Fabrizia Urbinati, Zulema R. Garcia, Roger P. Hollis, Sabine Geiger-Schredelseker, Aaron R. Cooper, Shantha Senadheera
  • LENTIVIRAL VECTOR FOR STEM CELL GENE THERAPY OF SICKLE CELL DISEASE
    Publication number: 20150224209
    Abstract: In various embodiments a recombinant lentiviral vector is provided comprising an expression cassette comprising a nucleic acid construct comprising an anti-sickling human beta globin gene encoding an anti-sickling-beta globin polypeptide comprising the mutations Gly16Asp, Glu22Ala and Thr87Gln, where the lentiviral vector is a TAT-independent and self-inactivating (SIN). In certain embodiments the vector additionally contains one or more insulator elements. The vectors are useful in gene therapy for the treatment of sickle cell disease.
    Type: Application
    Filed: September 10, 2013
    Publication date: August 13, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Donald B. KOHN, Fabrizia URBINATI, Zulema R. GARCIA, Roger HOLLIS, Sabine GEIGER-SCHREDELSEKER, Aaron COOPER, Shantha SENADHEERA